Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

研究方向

Apoptosis 相关产品(2721)

  • GC17369 structure
    GC17369Sorafenib
    CAS: 284461-73-0
    纯度: >99.50% / >99.00%

    索拉非尼Sorafenib是Raf-1和B-Raf的多激酶抑制剂,IC50分别为6 nM和22 nM;Sorafenib对VEGFR-2 VEGFR-3 PDGFR-β Flt-3和c-KIT也有抑制作用,IC50值分别为90 nM、20 nM、57 nM、59 nM和68 nM;索拉非尼能诱导自噬细胞凋亡和激活铁死亡,并具有抗肿瘤活性。

  • GC17386 structure
    GC17386YK-4-279
    CAS: 1037184-44-3
    纯度: >98.00%

    YK-4-279 阻断 RNA Helicase A (RHA) 与 EWS-FLI1(致癌蛋白)的结合。 YK-4-279 诱导细胞凋亡并对各种癌细胞显示出抗增殖活性。 YK-4-279 有一个手性中心,它可以分成两种对映体。 YK-4-279可用于癌症研究。

  • GC17393 structure
    GC17393Pyridoxine HCl
    CAS: 58-56-0
    纯度: >99.50%

    Pyridoxine HCl是维生素B6的盐酸盐形式,具有抗氧化剂的作用。

  • GC17394 structure
    GC173943-Nitropropionic acid
    CAS: 504-88-1
    纯度: >99.50%

    An inhibitor of complex II

  • GC17425 structure
    GC17425Sodium Tauroursodeoxycholate (TUDC)
    CAS: 35807-85-3
    纯度: >98.00%

    Tauroursodeoxycholate (Tauroursodeoxycholic acid; TUDCA) sodium 是一种内质网 (ER) 应激抑制剂。 Tauroursodeoxycholate 显着降低凋亡分子的表达,例如 caspase-3 和 caspase-12。 Tauroursodeoxycholate 也抑制 ERK。

  • GC17430 structure
    GC174302-Deoxy-D-glucose
    CAS: 154-17-6
    纯度: >98.00%

    2-Deoxy-D-glucose (2DG),是一种葡萄糖类似物,作为竞争性糖酵解抑制剂。

  • GC17448 structure
    GC17448AT-406 (SM-406)
    CAS: 1071992-99-8
    纯度: >98.00%

    A Smac mimetic and IAP antagonist

  • GC17450 structure
    GC17450GSK2606414
    CAS: 1337531-36-8
    纯度: >99.50% / >98.00%

    GSK2606414是一种具有口服活性的选择性蛋白激酶R样内质网激酶(PERK)抑制剂,IC 50 值为0.4nM。

  • GC17491 structure
    GC17491CITCO
    CAS: 338404-52-7
    纯度: >99.50%

    An agonist of human CAR

  • GC17512 structure
    GC17512A-1155463
    CAS: 1235034-55-5
    纯度: >99.50%

    A Bcl-xL inhibitor

  • GC17513 structure
    GC17513A-1331852
    CAS: 1430844-80-6
    纯度: >98.00%

    A Bcl-xL inhibitor

  • GC17555 structure
    GC17555NVP-TNKS656
    CAS: 1419949-20-4
    纯度: >98.00%

    A TNKS2 inhibitor

  • GC17577 structure
    GC17577NQDI 1
    CAS: 175026-96-7

    A selective inhibitor of ASK1

  • GC17586 structure
    GC17586Tofacitinib (CP-690550) Citrate
    CAS: 540737-29-9
    纯度: >99.50%

    A pan-JAK inhibitor

  • GC17602 structure
    GC17602Ac-DEVD-AFC
    CAS: 201608-14-2
    纯度: >99.00%

    A fluorogenic caspase subsrate

  • GC17603 structure
    GC17603PS-1145
    CAS: 431898-65-6
    纯度: >99.50%

    An IKKβ inhibitor

  • GC17621 structure
    GC17621TPCA-1
    CAS: 507475-17-4
    纯度: >99.50%

    A selective inhibitor of IKK2

  • GC17632 structure
    GC17632Maslinic Acid
    CAS: 4373-41-5
    纯度: >98.00%

    Maslinic Acid是一种五环三萜酸,广泛存在于橄榄和其他植物中。Maslinic Acid具有抗炎、抗氧化、抗肿瘤、降血糖和神经保护等多种生物活性。

  • GC17644 structure
    GC17644Bortezomib (PS-341)
    CAS: 179324-69-7
    纯度: >99.50%

    Bortezomib (PS-341) 作为一种具有抗肿瘤活性的二肽硼酸蛋白酶体抑制剂,可通过靶向苏氨酸残基,有效抑制Ki为0.6 nM的20S蛋白酶体。

  • GC17648 structure
    GC17648Dinaciclib(SCH727965)
    CAS: 779353-01-4
    纯度: >98.00%

    A CDK inhibitor

  • GC17649 structure
    GC17649Mebendazole
    CAS: 31431-39-7
    纯度: >99.00% / >98.00%

    A broad-spectrum anthelmintic that inhibits microtubules

  • GC17650 structure
    GC17650DAPK Substrate Peptide
    CAS: 386769-53-5

    A DAPK1 peptide substrate

  • GC17651 structure
    GC17651Sunitinib
    CAS: 557795-19-4
    纯度: >99.00% / >98.00%

    舒尼替尼Sunitinib(SU 11248)是一种具口服活性的多靶点受体酪氨酸激酶抑制剂,对血管内皮生长因子受体(VEGFR2)和血小板衍生生长因子受体(PDGFRβ)的IC 50 分别为80nM和2nM。

  • GC17655 structure
    GC17655Ganetespib (STA-9090)
    CAS: 888216-25-9
    纯度: >99.50%

    Ganetespib (STA-9090) (STA-9090) 是一种热休克蛋白 90 (HSP90) 抑制剂,在多种血液和实体肿瘤细胞系中表现出强效细胞毒性。 Ganetespib (STA-9090) 通过抑制 HIF-1α 在结直肠癌中具有抗血管生成作用;和 STAT3。